Journal Of Chemotherapy

The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.

The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.

Specific areas of focus include, but are not limited to:

· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;

· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;

· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;

· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;

· Drug interactions in single or combined applications;

· Drug resistance to antimicrobial and anticancer drugs;

· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;

· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;

· Pharmacogenetics and pharmacogenomics;

· Precision medicine in infectious disease therapy and in cancer therapy;

· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.

《化学治疗杂志》是一本国际多学科杂志，致力于快速发表高质量、同行评审的原创研究，涵盖抗菌和抗肿瘤化学治疗的各个方面。

该杂志发表原创实验和临床研究文章、最新评论、简短通讯和化学治疗各个方面的信件，涵盖感染的发病机制、诊断、治疗和控制，以及抗癌和免疫调节药物的使用。

具体重点领域包括但不限于：

· 抗菌、抗病毒、抗真菌、抗寄生虫和抗原虫药物；

· 抗癌经典和靶向化学治疗剂、生物制剂、激素药物、免疫调节药物、细胞治疗和基因治疗；

· 抗菌和抗癌药物的药代动力学和药效学特性；

·抗菌和抗癌药物的功效、安全性和毒理学概况；

· 单一或联合应用中的药物相互作用；

· 抗菌和抗癌药物的耐药性；

· 新型抗菌和抗癌药物的研究和开发，包括临床前、转化和临床研究；

· 抗菌和抗癌药物敏感性和/或耐药性的生物标志物；

· 药物遗传学和药物基因组学；

· 传染病治疗和癌症治疗中的精准医疗；

· 抗菌和抗癌疗法的药物经济学及其对患者、卫生服务和制药行业的影响。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-药学领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为1.9，平均审稿速度为 较慢,6-12周 ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。